Prescriptions filled during pregnancy for drugs with the potential of fetal harm
- 11 November 2009
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 116 (13), 1788-1795
- https://doi.org/10.1111/j.1471-0528.2009.02377.x
Abstract
Objective To assess the extent of prescriptions filled by pregnant women for drugs with recognised potential of fetal harm, and to document the outcomes of these pregnancies. Design Cross-sectional study. Population Quebec Pregnancy Registry. Methods We identified women who were pregnant during a five-year period and who were insured for prescription medications under the provincial drug plan. We obtained information on prescriptions filled during pregnancy for drugs with known potential of fetal harm. Main outcome measures Prescriptions filled for study drugs during the first, second and third trimesters of pregnancy; termination of pregnancy (TOP) or delivery, and whether the baby was diagnosed with a major congenital malformation (MCM). Results Of 109 344 women, 56% filled at least one prescription for a medication during pregnancy; 6.3% filled at least one prescription for a drug known to pose a risk to the fetus. Overall, 47% (95% CI, 45.8-48.2) of pregnancies exposed to drugs under study ended in TOP versus 36.2% (95% CI, 35.9-36.5) of those not exposed; 8.2% (95% CI, 8.0-10.0) of live births were diagnosed with an MCM during the first year of life versus 7.1% (95% CI, 6.9-7.3) of those not exposed. Conclusions This study documents an important level of prescriptions filled during pregnancy for drugs harmful to the developing fetus. The proportions of both TOPs and babies born with MCMs were elevated compared with the expected values. Clinicians caring for women during pregnancy should conduct a medication inventory prior to a planned pregnancy, or as soon as an unplanned pregnancy is recognised.This publication has 21 references indexed in Scilit:
- Duration of antidepressant use during pregnancy and risk of major congenital malformationsThe British Journal of Psychiatry, 2008
- Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancyAmerican Journal of Obstetrics and Gynecology, 2008
- Agreement between administrative databases and medical charts for pregnancy‐related variables among asthmatic womenPharmacoepidemiology and Drug Safety, 2008
- Prescription drug use among fathers and mothers before and during pregnancy. A population‐based cohort study of 106 000 pregnancies in Norway 2004–2006British Journal of Clinical Pharmacology, 2008
- Risk of congenital anomalies in pregnant users of statin drugsBritish Journal of Clinical Pharmacology, 2007
- Isotretinoin, pregnancies, abortions and birth defects: a population‐based perspectiveBritish Journal of Clinical Pharmacology, 2007
- First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosageBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2006
- Prescription drug use in pregnancyAmerican Journal of Obstetrics and Gynecology, 2004
- Prescription drugs and pregnancyExpert Opinion on Pharmacotherapy, 2003
- Teratology in the 20th century: Environmental causes of congenital malformations in humans and how they were establishedNeurotoxicology and Teratology, 2003